Keyphrases
Immunomodulating
100%
Cutaneous Squamous Cell Carcinoma (cSCC)
100%
Immunosuppressed
81%
Tumor
45%
Solid Organ Transplant Recipients
45%
Immunocompromised Patients
36%
Chronic Lymphocytic Leukemia
36%
Survival Rate
27%
Chronic Kidney Disease
27%
Cox Regression Analysis
27%
Immunosuppression
27%
Psoriasis
18%
Leukemia Patients
18%
Rheumatoid Arthritis
18%
Etiology
9%
Chemotherapy
9%
Treatment Efficacy
9%
High Risk
9%
Clinical Features
9%
Psoriasis Disease
9%
Retrospective Analysis
9%
Radiotherapy
9%
Recurrence Rate
9%
Primary Tumor
9%
Clinical Treatment
9%
Worse Outcome
9%
Disease Groups
9%
Disease-free Survival
9%
Lesion Size
9%
Clinical Survival
9%
Rheumatoid Arthritis Patients
9%
Immunosuppressive Agents
9%
Overall Survival Rate
9%
Positive Margins
9%
Oncological Treatment
9%
Positive Resection Margin
9%
Systemic Lupus Erythematous
9%
Medicine and Dentistry
Skin Carcinoma
100%
Survival Rate
45%
Neoplasm
45%
B-Cell Chronic Lymphocytic Leukemia
36%
Proportional Hazards Model
27%
Chronic Kidney Disease
27%
Immunosuppressive Treatment
27%
Rheumatoid Arthritis
27%
Psoriasis
27%
Inflammatory Arthritis
27%
Clinical Feature
9%
Cancer Therapy
9%
Primary Tumor
9%
Overall Survival
9%
Systemic Lupus Erythematosus
9%
Recurrence Risk
9%
Disease Free Survival
9%
Immunomodulating Agent
9%
Surgical Margin
9%
Radiation Therapy
9%